Other substances

Proscillaridin

A cardiac glycoside.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

2
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Proscillaridin is a natural glycoside drug. It has potential cytotoxic and anticancer properties due to topoisomerase I and II activity inhibition and cytotoxic/cytostatic effects on glioblastoma cell lines (DrugBank).

Proscillaridin on PubChem
Proscillaridin on Wikipedia

 

Structure image - Proscillaridin

C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O

Supporting references

Link Tested on Impact factor Notes Publication date
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020
Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate
Preprint 		Calu-3 human airway epithelial cells higher IC50 value in Calu-3 cells than VERO E6 cells May/12/2020

AI-suggested references

Link Publication date
Computational gene expression profiling in the exploration of biomarkers, non-coding functional RNAs and drug perturbagens for COVID-19
Nov/23/2020
Export (.csv)